Intrigued by ULU -- Uluru, Inc.
ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex(TM) Aggregate technology and OraDisc(TM) transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com. For further information about Altrazeal(TM), please visit www.altrazeal.com.
As of March 24, 2010, there were 81,946,657 shares of the registrant’s Common Stock, $0.001 par value per share, issued and outstanding.
Effective April 1, 2010, the Board of Directors of ULURU Inc. (the “Company”) appointed Dr. Jeffrey A. Stone to serve as a director of the Company.
Dr. Stone, age 53, is currently President of Wound Care Consultants. He is a past president Texas Affiliate of the American Diabetes Association. Dr. Stone received his medical degree from the College of Osteopathic Medicine of the Pacific and a Master of Public Health from Harvard University. He completed a residency in aerospace medicine and a fellowship in hyperbaric medicine and wound care at the U.S. Air Force School of Aerospace Medicine at Brooks Air Force Base. He is certified in hyperbaric medicine and board certified in aerospace medicine. He is a Diplomate of the American Academy of Wound Care Management and a Certified Wound Specialist having been active in the wound field for over 20 years.
Dr. Stone will serve on the Company’s Audit, Compensation, and Nominating and Corporate Governance Committees. In connection with his appointment to the Board, Dr. Stone was granted an option to purchase 50,000 shares of common stock at an exercise price of $0.17, the closing price of the Company’s common stock on April 1, 2010.
ULURU Inc. to Present Altrazeal(TM) Clinical Evidence at the 2010 American Professional Wound Care Association (APWCA) National Clinical Conference
Oral Presentation on Pain Relief, Moisture Management and Restoring Quality Of Life
ADDISON, Texas, April 8 /PRNewswire-FirstCall/ --ULURU Inc. (NYSE Amex: ULU) announced today that t, April 8, 2010 /PRNewswire via COMTEX/ -- ULURU Inc. (NYSE Amex: ULU) announced today that the Company will be presenting clinical data at the 2010 American Professional Wound Care Association(APWCA) National Conference in Philadelphia, PA April 8-11, 2010. At the conference, Altrazeal(TM) clinical evidence, best clinical practices, and advanced clinical applications will be showcased in both podium and poster presentations.
Dr. Gregory Bohn, MD, FACS, Medical Director of the Trinity Center for Wound Care and Hyperbaric Medicine in Bettendorf, Iowa, will be giving a podium presentation on Saturday, April 10, titled" Transforming Powder Wound Dressing Relieves Pain and Manages Moisture, Restoring Quality of Life". In addition, Dr. Bohn will present numerous additional posters on topics including, the use of Altrazeal(TM) in conjunction with mesh skin graft fixation, Altrazeal(TM) as a cost-effective management technique in difficult to heal wounds, use of Altrazeal with negative pressure wound therapy and the unique physical properties of Altrazeal(TM) and their potential impact on wound healing.
Commenting on the clinical data being presented, Dr. Bohn stated, "I use Altrazeal(TM) extensively in my clinic and have achieved excellent clinical results in an extensive range of wound types and have demonstrated the cost effectiveness of the dressing. The presentations at APWCA will demonstrate techniques and cases where we have had great success in treating patients with Altrazeal(TM) as part of our treatment protocol."
Renaat Van den Hooff, President and CEO of ULURU Inc., commented, "We are extremely pleased that Dr. Bohn has been chosen to give an oral presentation on Altrazeal(TM). This forum will give Altrazeal(TM) great visibility at this prestigious conference. The clinical data being presented further adds to the extensive data supporting the use of Altrazeal(TM) in acute and chronic wounds and the economic and patient benefits Altrazeal(TM) provides. The conference gives us the opportunity to discuss Altrazeal(TM) with many clinical professionals who have used the product as well as the forum to introduce Altrazeal(TM) to the clinicians who have yet to experience the benefits to be gained from using the product."
In addition, ULURU will be presenting a poster on best clinical practice with Altrazeal(TM) showing application techniques for treating three specific wound types: diabetic foot ulcers, venous ulcers and pressure ulcers.
ULURU will also have a booth in the exhibit area at the APWCA to provide information on Altrazeal(TM) to wound care professionals, including application techniques, best clinical experience, and reimbursement.
Information about APWCA and the annual conference can be found at www.APWCA.org.
Recent volume surge is impressive as well:
Tuesday, Apr 13 volume is already well over 7M at the time of this post.
Monday, Apr 12, 2010 0.17 0.196 0.165 0.185 9,567,929
Friday, Apr 9, 2010 0.168 0.171 0.155 0.16 8,075,730
Thursday, Apr 8, 2010 0.17 0.18 0.16 0.16 8,494,218
Wednesday, Apr 7, 2010 0.1525 0.167 0.1517 0.16 2,302,697
Tuesday, Apr 6, 2010 0.1579 0.1599 0.15 0.1524 1,687,975
Monday, Apr 5, 2010 0.1699 0.1699 0.1441 0.15 4,010,702
Thursday, Apr 1, 2010 0.17 0.172 0.16 0.165 5,276,511
